A 51-year-old man with acromegaly underwent transsphenoidal surgery 6 months ago. Despite treatment, he remains symptomatic with coarse facial features and hand enlargement. Current vital signs: BP 145/92 mmHg, HR 88/min. Laboratory studies show elevated IGF-1 (520 ng/mL; normal <300) and growth hormone 8.5 ng/mL. MRI shows no residual pituitary adenoma. He denies headaches or vision changes. His endocrinologist prescribes a drug blocking peripheral growth hormone receptors rather than inhibiting pituitary hormone release. Which agent was most likely prescribed?
- A)PegvisomantGABARITO
- B)Clomiphene
- C)Cabergoline
- D)Octreotide
- E)Leuprolide
Explicação
Pegvisomant is a growth hormone receptor antagonist used in acromegaly when control remains inadequate. It lowers IGF 1 production in peripheral tissues even though circulating growth hormone levels may remain elevated. Ver explicação completa e trilha adaptativa →